Total

N = 16

KW group

N = 8

MY group

N = 8

p

Sex, n (%)

    Male

    Female

8 (50.0)

8 (50.0)

4 (50.0)

4 (50.0)

4 (50.0)

4 (50.0)

-

Age at diagnosis (years)

    mean ± standard deviation

    range

5.9 ± 4.6

0.15-13.2

2.7 ± 2.0

0.15-5.8

10.3 ± 3.3

4.0-13.2

0.0002

Weight at diagnosis (kg)

    mean ± standard deviation

    range

26.1 ± 20.2

4.5-60.0

12.6 ± 5.6

4.5-23.4

44.1± 18.6

14.9-60.0

0.006

Body mass index (kg/m²)

    mean ± standard deviation

    range

17.1 ± 3.5

13.3-24.0

15.6 ± 1.8

13.3-19.2

19.0 ± 4.5

13.3-24.0

0.09

COVID , n (%)

6 (37.5)

2 (25.0)

4 (50.0)

0.33

PCR-positive COVID, n (%)

4 (25.0)

0 (0.0)

4 (50.0)

0 .024

Onset of symptoms to diagnosis (days)`

mean ± standard deviation

range

4.7 ± 2.4

1.0-9.0

5.5 ± 2.5

2.0-9.0

3.8 ± 2.0

1.0-7.0

0.21

Fever, n (%)

14 (100.0)

8 (100.0)

8 (100.0)

-

Dermatological signs, n (%)

9 (64.3)

7 (87.5)

2 (25.0)

0.036

Conjunctivitis, n (%)

8 (50.0)

5 (62.5)

3 (37.5)

0.28

Cheilitis, n (%)

8 (50.0)

5 (62.5)

3 (37.5)

0.28

Lymphadenopathies, n (%)

11 (68.7)

7 (87.5)

4 (50.0)

0.12

Chest pain, n (%)

3 (18.7)

0 (0.0)

3 (37.5)

0.07

Gastrointestinal symptoms, n (%)

10 (64.3)

4 (50.0)

6 (75.0)

0.19

Respiratory symptoms, n (%)

4 (25)

1 (12.5)

3 (37.5)

0.12

Neurological symptoms, n (%)

4 (28.5)

2 (25.0)

2 (25.0)

0.73

ENT symptoms, n (%)

9 (64.3)

5 (62.5)

4 (50)

0.87

Intravenous immunoglobulins, n (%)

 1 dose 2 g/kg

 2 doses 1 g/kg/dose

9 (64.3)

7 (35.7)

8 (100.0)

0 (0.0)

1 (16.7)

6 (83.3)

0.0013